|
1
|
Mehenni H, Gehrig C, Nezu J, et al: Loss
of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for
allelic and locus heterogeneity. Am J Hum Genet. 63:1641–1650.
1998.
|
|
2
|
Lim W, Olschwang S, Keller JJ, et al:
Relative frequency and morphology of cancers in STK11 mutation
carriers. Gastroenterology. 126:1788–1794. 2004.
|
|
3
|
Hearle N, Schumacher V, Menko FH, et al:
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.
Clin Cancer Res. 12:3209–3215. 2006.
|
|
4
|
Fenton H, Carlile B, Montgomery EA, et al:
LKB1 protein expression in human breast cancer. Appl
Immunohistochem Mol Morphol. 14:146–153. 2006.
|
|
5
|
Ji H, Ramsey MR, Hayes DN, et al: LKB1
modulates lung cancer differentiation and metastasis. Nature.
448:807–810. 2007.
|
|
6
|
Sanchez-Cespedes M, Parrella P, Esteller
M, et al: Inactivation of LKB1/STK11 is a common event in
adenocarcinomas of the lung. Cancer Res. 62:3659–3662. 2002.
|
|
7
|
Wang ZJ, Churchman M, Campbell IG, et al:
Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus
(19p13.3) in sporadic ovarian tumours. Br J Cancer. 80:70–72.
1999.
|
|
8
|
Ylikorkala A, Avizienyte E, Tomlinson IP,
et al: Mutations and impaired function of LKB1 in familial and
non-familial Peutz-Jeghers syndrome and a sporadic testicular
cancer. Hum Mol Genet. 8:45–51. 1999.
|
|
9
|
Reck M, von Pawel J, Zatloukal P, et al:
Phase III trial of cisplatin plus gemcitabine with either placebo
or bevacizumab as first-line therapy for nonsquamous non-small-cell
lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009.
|
|
10
|
Cunningham D, Chau I, Stocken DD, et al:
Phase III randomized comparison of gemcitabine versus gemcitabine
plus capecitabine in patients with advanced pancreatic cancer. J
Clin Oncol. 27:5513–5518. 2009.
|
|
11
|
Chan S, Romieu G, Huober J, et al: Phase
III study of gemcitabine plus docetaxel compared with capecitabine
plus docetaxel for anthracycline-pretreated patients with
metastatic breast cancer. J Clin Oncol. 27:1753–1760. 2009.
|
|
12
|
Mini E, Nobili S, Caciagli B, Landini I
and Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol.
17v7–v12. (Suppl 5)2006.
|
|
13
|
Wong A, Soo RA, Yong WP and Innocenti F:
Clinical pharmacology and pharmacogenetics of gemcitabine. Drug
Metab Rev. 41:77–88. 2009.
|
|
14
|
Bergman AM, Pinedo HM and Peters GJ:
Determinants of resistance to 2′,2′-difluorodeoxycytidine
(gemcitabine). Drug Resist Update. 5:19–33. 2002.
|
|
15
|
Katajisto P, Vallenius T, Vaahtomeri K, et
al: The LKB1 tumor suppressor kinase in human disease. Biochim
Biophys Acta. 1775:63–75. 2007.
|
|
16
|
Zhuang ZG, Di GH, Shen ZZ, Ding J and Shao
ZM: Enhanced expression of LKB1 in breast cancer cells attenuates
angiogenesis, invasion, and metastatic potential. Mol Cancer Res.
4:843–849. 2006.
|
|
17
|
Bonner WM, Redon CE, Dickey JS, et al:
GammaH2AX and cancer. Nature Rev Cancer. 8:957–967. 2008.
|
|
18
|
Mah LJ, El-Osta A and Karagiannis TC:
gammaH2AX: a sensitive molecular marker of DNA damage and repair.
Leukemia. 24:679–686. 2010.
|
|
19
|
Al-Ejeh F, Darby JM and Brown MP: The La
autoantigen is a malignancy-associated cell death target that is
induced by DNA-damaging drugs. Clin Cancer Res. 13:5509s–5518s.
2007.
|
|
20
|
Dufau I, Frongia C, Sicard F, et al:
Multicellular tumor spheroid model to evaluate spatio-temporal
dynamics effect of chemotherapeutics: application to the
gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC
Cancer. 12:152012.
|
|
21
|
Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K
and Linn S: Molecular mechanisms of mammalian DNA repair and the
DNA damage checkpoints. Ann Rev Biochem. 73:39–85. 2004.
|
|
22
|
Lee JH and Paull TT: ATM activation by DNA
double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science.
308:551–554. 2005.
|
|
23
|
Zou L and Elledge SJ: Sensing DNA damage
through ATRIP recognition of RPA-ssDNA complexes. Science.
300:1542–1548. 2003.
|
|
24
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010.
|
|
25
|
Lee JH and Paull TT: Direct activation of
the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science.
304:93–96. 2004.
|
|
26
|
Bardenheuer W, Lehmberg K, Rattmann I, et
al: Resistance to cytarabine and gemcitabine and in vitro selection
of transduced cells after retroviral expression of cytidine
deaminase in human hematopoietic progenitor cells. Leukemia.
19:2281–2288. 2005.
|
|
27
|
Bergman AM, Eijk PP, Ruiz van Haperen VW,
et al: In vivo induction of resistance to gemcitabine results in
increased expression of ribonucleotide reductase subunit M1 as the
major determinant. Cancer Res. 65:9510–9516. 2005.
|
|
28
|
Nakahira S, Nakamori S, Tsujie M, et al:
Involvement of ribonucleotide reductase M1 subunit overexpression
in gemcitabine resistance of human pancreatic cancer. Int J Cancer.
120:1355–1363. 2007.
|
